Anti-vascular therapy: A new approach to cancer treatment

Western Journal of Medicine

Volumn 172, Issue 1, 2000, Pages 39-42

  Hayes, A L ^a   Li, L Y ^a   Lippman, M E ^a  

^a GEORGETOWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0005345702     PISSN: 00930415     EISSN: None     Source Type: Journal    
DOI: 10.1136/ewjm.172.1.39     Document Type: Article

References (32)

1. Bailer JC, Gornik HL. Cancer undefeated. N Engl J Med 1997;336:1569-1574.
2. Bowen W. The effects of surgical interference with the blood supply on the growth of transplanted carcinomata and sarcomata. Sci Rep Imperial Cancer Res Fund 1908;3:146-158.
3. Alguire GH. The transparent chamber technique as a tool in experimental tumor therapy. In: Symposia: approaches to tumor chemotherapy. Washington, DC: American Association for the Advancement of Science, 1947:13-26.
4. Tannock IF. The relationship between cell proliferation and the vascular system in a transplanted mouse mammary tumour. Br J Cancer 1968;22:258-273.
5. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971;285:1182-1186.
6. Liotta L, Kleinerman J, Saidel G. Quantitative relationships of intravascular tumor cells, tumor vessels and pulmonary metastasis following tumor implantation. Cancer Res 1974;34:997-1004.
7. Folkman J. Anti-angiogenesis: new concept for therapy of solid tumors. Ann Surg 1972;175:409-416.
8. Gimbrone M, Leapman S, Cotran R, et al. Tumor dormancy in vivo by prevention of neo-vascularisation. J Exp Med 1972;136:261-276.
9. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996;86:353-364.
10. Smith-McCune KK, Weidner N. Demonstration and characterization of the angiogenic properties of cervical dysplasia. Cancer Res 1994;54:800-804.
11. Weidner N. Current pathological methods for measuring intratumoral microvessel density within breast carcinoma and other solid tumors. Breast Cancer Res Treat 1996;36:169-180.
12. Suri C, Jones P, Patan S, et al. Requisite role of angiopoietin-1, a ligand for the TIE-2 receptor during embryonic angiogenesis. Cell 1996;87:1171-1180.
13. Maisonpierre PC, Suri C, Jones PF, et al. Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science 1997;277:55-60.
14. Senger DR, Galli SJ, Dvorak AM, et al. Tumor cells secrete a vascular permeability factor that promotes the accumulation of ascites fluid. Science 1983;219:983-985.
15. Leung DW, Cachaines G, Kwang W-J, et al. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 1989;246:1306-1309.
16. Senger DR, Perruzzi CA, Feder J, et al. A highly conserved vascular permeability factor secreted by a variety of human and rodent tumor cell lines. Cancer Res 1986;46:5629-5632.
17. Schweiki D, Itin A, Soffe D, et al. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia initiated angiogenesis. Nature 1992;359:843-845.
18. Vlodavsky I, Bashkin P, Ishai-Michaeli R, et al. Sequestration and release of basic fibroblast growth factor. Ann N Y Acad Sci 1991;638:207-220.
19. Nguyen M, Watanabe H, Budson AE, et al. Elevated levels of an angiogenic peptide, basic fibroblast growth factor, in the urine of patients with a wide spectrum of cancers. J Natl Cancer Inst 1994;86:356-361.
20. Mcleskey S, Kurebayashi J, Honig S, et al. Fibroblast growth factor 4 transfection of MCF-7 cells produces cell lines that are tumorigenic and metastatic in ovarectomised or tamoxifen treated athymic nude mice. Cancer Res 1993;53:2169-2177.
21. Kim KJ, Li B, Winer J, et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 1993;362:841-844.
22. Czubayko F, Liaudet-Coopman ED, Aigner A, et al. A secreted FGF-binding protein can serve as the angiogenic switch in human cancer. Nature Med 1997;3:1137-1140.
23. Relf M, Le Jeune S, Scott PA, et al. Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor beta-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis. Cancer Res 1997;57:963-969.
24. Good D, Rastinejad F, Polverini PJ, et al. A rumor suppresser dependent inhibitor of angiogenesis is immunologically and functionally indistinguishable from a fragment of thrombospondin. Proc Natl Acad Sci 1990;87:6624-6628.
25. Dameron KM, Volpert OV, Tainsky AM, et al. Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science 1994;265:1582-1584.
26. O'Reilly MS, Holmgren L, Shing Y, et al. Angiostatin: a novel angiogenesis inhibitor that mediates suppression of metastases by a Lewis lung carcinoma. Cell 1994;79:315-328.
27. O'Reilly MS, Holmgren L, Chen C, et al. Angiostatin induces and sustains dormancy of human primary tumors in mice. Nat Med 1996;2:689-692.
28. O'Reilly MS, Boehm T, Shing Y, et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 1997;88:277-285.
29. Boehm T, Folkman J, Browder T, et al. Anti-angiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature 1997;390:404-407.
30. Huang X, Molema G, King S, et al. Tumor infarction in mice by antibody-directed targeting of tissue factor to tumor vasculature. Science 1997;275:547-550.
31. 3 antagonists promote tumour regression by inducing apoptosis of angiogenic blood vessels. Cell 1994;79:1157-1164.
32. Kudelka AP, Verschraegen CF, Loyer E. Complete remission of metastatic cervical cancer with the angiogenesis inhibitor TNP-470. N Engl J Med 1998;338:991-992.